Introduction to the CANWARD Study (2007-2009).
暂无分享,去创建一个
[1] J. Karlowsky,et al. Analysis of 3789 in- and outpatient Escherichia coli isolates from across Canada--results of the CANWARD 2007-2009 study. , 2011, Diagnostic microbiology and infectious disease.
[2] M. Mulvey,et al. Comparison of community-associated and health care-associated methicillin-resistant Staphylococcus aureus in Canada: results of the CANWARD 2007-2009 study. , 2011, Diagnostic microbiology and infectious disease.
[3] J. Karlowsky,et al. In vitro activity of ceftobiprole against frequently encountered aerobic and facultative Gram-positive and Gram-negative bacterial pathogens: results of the CANWARD 2007-2009 study. , 2011, Diagnostic microbiology and infectious disease.
[4] J. Blondeau,et al. Antimicrobial susceptibility of 15,644 pathogens from Canadian hospitals: results of the CANWARD 2007-2009 study. , 2011, Diagnostic microbiology and infectious disease.
[5] S. Poutanen,et al. In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007-2009 study. , 2011, Diagnostic microbiology and infectious disease.
[6] M. Mulvey,et al. Characterization of Acinetobacter baumannii and meropenem-resistant Pseudomonas aeruginosa in Canada: results of the CANWARD 2007-2009 study. , 2011, Diagnostic microbiology and infectious disease.
[7] R. Rennie,et al. Prevalence of antimicrobial resistant pathogens from blood cultures from Canadian hospitals: results of the CANWARD 2007-2009 study. , 2011, Diagnostic microbiology and infectious disease.
[8] M. Mulvey,et al. Prevalence and characterization of extended-spectrum β-lactamase- and AmpC β-lactamase-producing Escherichia coli: results of the CANWARD 2007-2009 study. , 2011, Diagnostic microbiology and infectious disease.
[9] F. Martínez Sagasti,et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. , 2010, JAMA.
[10] K. Reed,et al. Changing prevalence of Escherichia coli with CTX-M-type extended-spectrum beta-lactamases in outpatient urinary E. coli between 2003 and 2008. , 2010, Diagnostic microbiology and infectious disease.
[11] B. Murray,et al. Antibiotic-resistant bugs in the 21st century--a clinical super-challenge. , 2009, The New England journal of medicine.
[12] A. Kennedy,et al. Epidemiology and Virulence of Community-Associated MRSA , 2009 .
[13] Qiwen Yang,et al. Phenotypic and Genotypic Characterization of Enterobacteriaceae with Decreased Susceptibility to Carbapenems: Results from Large Hospital-Based Surveillance Studies in China , 2009, Antimicrobial Agents and Chemotherapy.
[14] M. Mulvey,et al. Comparison of community-associated and health care-associated methicillin-resistant Staphylococcus aureus in Canada: results from CANWARD 2007. , 2009 .
[15] R. Bonomo,et al. The continuing challenge of ESBLs. , 2007, Current opinion in pharmacology.
[16] B. Wickes,et al. First Report of the Emergence of CTX-M-Type Extended-Spectrum β-Lactamases (ESBLs) as the Predominant ESBL Isolated in a U.S. Health Care System , 2007, Antimicrobial Agents and Chemotherapy.
[17] K. Bush,et al. Carbapenemases: the Versatile β-Lactamases , 2007, Clinical Microbiology Reviews.